NCT07185022 Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
| NCT ID | NCT07185022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Second Hospital of Anhui Medical University |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 282 participants |
| Start Date | 2026-01-06 |
| Primary Completion | 2030-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 282 participants in total. It began in 2026-01-06 with a primary completion date of 2030-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA) * The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction) * Intra-arterial thrombolysis was administered within the following time windows: 1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA; 2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \<30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume. * Signed informed consent obtained Exclusion Criteria: * Pre-stroke mRS ≥ 2 * Secondary MeVO or severe stenosis caused by endovascular therapy * Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders * Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory * Platelet count \<100 × 10⁹/L, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \>3.0 * Persistent and uncontrolled hypertension, defined as systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg * History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage * Presence of arteriovenous malformations or brain tumors with mass effect * Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months * Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \<30 mL/min or serum creatinine \>220 μmol/L (2.5 mg/dL) * Patients with known allergy to thrombolytic agents or their excipients * Patients with known allergy to iodinated contrast agents or other established contraindications * Pregnant or current breastfeeding * Presence of severe systemic comorbidities with a life expectancy of less than 3 months * Deemed unsuitable for participation by the investigator for any reason
Contact & Investigator
Qi Li, professor
PRINCIPAL INVESTIGATOR
The Second Hospital of Anhui Medical University
Frequently Asked Questions
Who can join the NCT07185022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07185022 currently recruiting?
Yes, NCT07185022 is actively recruiting participants. Contact the research team at qili_md@126.com for enrollment information.
Where is the NCT07185022 trial being conducted?
This trial is being conducted at Fuyang, China, Fuyang, China, Hefei, China, Lu'an, China and 2 additional locations.
Who is sponsoring the NCT07185022 clinical trial?
NCT07185022 is sponsored by The Second Hospital of Anhui Medical University. The principal investigator is Qi Li, professor at The Second Hospital of Anhui Medical University. The trial plans to enroll 282 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.